Skip to main content

Table 2 Characteristics of the 751 patients who entered the operating room according to period of workup imaging

From: Has the non-resection rate decreased during the last two decades among patients undergoing surgical exploration for pancreatic adenocarcinoma?

 

Period 1

Period 2

P value

n

256

495

< 0.01

Sex Ratio (M/F)

1.11

1.02

0.58

Median Age (range)

67 (32–85)

65 (25–86)

0.19

Mean BMI (±SD)

25.3 (±4.64)

24.4 (±4.1)

0.01

Biliary Stenting (%)

118 (46)

300 (61)

< 0.001

Work up Imaging (%)

 CT-scan

224 (100)

527 (100)

1

 Liver Magnetic Resonance Imaging

35 (14)

372 (75)

< 0.001

 Positron Emission Tomography

7 (2.7)

62 (13)

< 0.001

Median delay CT-Surgery (days) (range)

21 (1–55)

16 (1–48)

< 0.001

Mean CA 19–9 serum level* (UI) (±SD) (after jaundice resolution)

552 (±937)

552 (±1275)

1

Explorative Laparoscopy (%)

23 (9)

59 (12)

0.27

Neoadjuvant Treatment (%)

118 (46)

219 (44)

0.64

Type of Surgery (%)

 Exploration without Resection

61 (24)

123 (25)

0.79

 Pancreaticoduodenectomy

152 (59)

232 (47)

0.001

 Distal Pancreatectomy

35 (14)

111 (22)

0.005

 Total Pancreatectomy

8 (3)

29 (6)

0.11

 Venous Resection

36 (14)

123 (25)

< 0.001

 Arterial Resection

0

19 (4)

< 0.001

 En-bloc Resection of Neighbours Organs

16 (6)

27 (5)

0.74

Reason of Non-resection (%)

 Carcinomatosis

15 (6)

20 (4)

0.28

 Liver Metastasis

12 (5)

37 (7)

0.16

 Vascular Invasion

33 (13)

42 (8)

0.07

 Total

60 (23)

99 (20)

0.3

 Distant Lymph Node Invasion

1 (0.4)

24 (5)

< 0.001

 Mean Size of Extra Pancreatic Metastasis (mm) (±SD)

7.9 (±5.2)

6.4 (±3.9)

< 0.01

Morbidity (%)(resected patients)

195

372

 

 Overall / Grades 3 to 5

93 (48) / 28 (14)

186 (35) / 57 (15)

0.66 / 0.3

 Hemorrhage

22 (11)

25 (11)

0.08

 Clinically Revelant Postoperative Pancreatic Fistula

37 (19)

71 (13)

0.99

 Reintervention

18 (9)

25 (4.7)

0.31

30- / 90-days Mortality (%)(resected patients)

11 (5.6) / 16 (8.2)

13 (3.5) / 14 (3.8)

0.27 / 0.03

Pathologic Findings (resected patients)

 T1/2 (%)

71 (36)

134 (36)

0.74

 T3/4 (%)

124 (64)

238 (64)

0.93

 Median Number of Examined Lymph Nodes (range)

10 (2–23)

15 (4–44)

< 0.01

 N+ (%)

99 (51)

230 (62)

0.01

 R1 (%)

81 (42)

177 (48)

0.18

 Perineural Invasion (%)

122 (63)

263 (71)

0.06

Adjuvant Treatment (%)(resected patients)

91 (47)

261 (70)

< 0.001

  1. (BMI Body Mass Index; SD Standard Deviation, * at diagnosis)